Aims: The aim of this study was to determine the impact of diabetes mellitus (DM) on short-term overall survival and time to recurrence (TTR) in breast cancer patients, and examine the impact of breast cancer on glycemic control in DM. Methods: From a data set of newly diagnosed breast cancer patients (2007)(2008)(2009)(2010)(2011), we identified 109 patients with DM and 109 matched controls. Results: Hemoglobin A1c among cases did not significantly change over 1 year (p = 0.10). Cases and controls showed no differences in OS (hazard ratio: 1.25; 95% CI: 0.49-3.17) during the median follow-up of 2.2 years (range: 0.1-4.9 years) and no differences in TTR (hazard ratio: 1.00; 95% CI: 0.14-7.10). Conclusion: DM did not adversely affect metabolic control, short-term OS or TTR. KEYWORDSCoexisting diabetes mellitus (DM) and cancer has been a topic of increasing interest [1]. DM is associated with an increased risk of development of many types of cancers [2][3][4]. Moreover, several studies have indicated that coexisting DM is associated with greater mortality in several types of cancers, including colorectal, endometrial, pancreas, liver and bladder [5,6]. A relationship between hyperglycemia and cancer mortality has also been noted [7,8].The link between DM and breast cancer is of particular interest, given the common risk factors of obesity, diet and hyperinsulinemia [2][3][4]. Current hypotheses regarding mechanisms of the link between DM and breast cancer can be found in two recent reviews [2,5]. Postulated Practice points• The link between diabetes mellitus (DM) and breast cancer is of particular interest, given the common risk factors of obesity, diet and hyperinsulinemia.• Previous studies typically have not examined how DM might affect breast cancer mortality or how breast cancer might alter outcomes of patients with DM in a single analysis.• The purpose of this study was to examine whether breast cancer and its treatment affected glycemic control and therapy for DM and to assess its impact on short-term overall survival and time to recurrence.• The presence of breast cancer and its treatment did not negatively affect metabolic control among patients with DM in this cohort.• DM did not appear to affect either breast cancer overall survival or time to recurrence in the short term.For reprint orders, please contact: reprints@futuremedicine.com

Aim:This case–control study examined the impact of diabetes mellitus (DM) on survival in lung cancer patients and lung cancer on glycemic control in DM.Materials & methods:Patients with a new lung cancer diagnosis and DM (n = 124) were matched to 124 lung cancer patients without DM. Laboratory results and DM and cancer therapies were obtained from electronic records.Results:Five-year overall survival for lung cancer patients with and without DM was 20 versus 29% (p = .12). Glycemic control among DM patients did not change significantly with time.Conclusion:DM does not cause adverse impact on lung cancer survival. Lung cancer does not affect glycemic control.

No abstract

Aim:We aimed to determine the effect of diabetes mellitus (DM) on survival in pancreatic cancer and effects of pancreatic cancer on glycemic control in DM.Materials & methods:Patients with pancreatic cancer from 2007 to 2015, with and without DM, were matched 1:1. We compared characteristics between the groups and assessed 2-year survival with Kaplan–Meier analysis.Results:In patients with DM, hemoglobin A1c decreased significantly over time (p = 0.01). In survival analysis, 2-year overall survival estimates were 15% (95% CI: 8–24%) for DM patients versus 26% (95% CI: 17–36%) for non-DM patients (p = 0.55). The hazard ratio for matched pairs was 1.15 (95% CI: 0.75–1.77; p = 0.51).Conclusion:DM did not decrease survival in pancreatic cancer. Pancreatic cancer did not affect glycemic control.

The impact of diabetes mellitus (DM) on survival in patients with colorectal cancer and the impact of colorectal cancer on glycemic control were examined. Materials & methods: Patients with colorectal cancer with and without DM were matched 1:1 (2007-2015). Characteristics were compared between the two groups and survival assessed with the Kaplan-Meier method. Mixed models compared hemoglobin A 1c and glucose levels over time. Results: In both groups, glucose values decreased during the year following cancer diagnosis (p < 0.001). 5-year overall survival was 56% (95% CI: 42-68%) for DM patients versus 57% (95% CI: 43-69%) for non-DM patients (p = 0.62). Conclusion: DM did not adversely impact survival of patients with colorectal cancer. Colorectal cancer did not affect glycemic control.